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The players involved in Vascular Endothelial Growth Factor 
(VEGF) Production in Astrocytoma SF268 
Samer Michel Nicolas 
ABSTRACT 
Angiogenesis, the fabrication of neo-blood vessels (capillaries), is one of the major 
hallmarks of cancer and is one of the underlying mechanisms for the tumor’s 
aggressiveness and metastasis. When faced with hypoxic conditions, cancer cells release 
various growth and angiogenic factors that lead to the activation of endothelial cells 
(ECs). The activated ECs then evolve into endothelial tubes that mature into capillaries 
which supply the tumor cells with the necessary nutrients and oxygen for their survival, 
proliferation and metastasis. Vascular endothelial growth factor (VEGF) is one of the 
most important angiogenic modulators that has been intensely studied for its potential in 
treating various angiogenic pathologies. However, the pathway(s) involved in VEGF’s 
production and secretion have not been fully deciphered yet, at least not for astrocytoma. 
In this study, we aim to determine the different pathways and signaling proteins 
involved in VEGF production in astrocytoma. The astrocytomas were subjected to either 
hypoxic conditions or to stimulation by the epithelial growth factor (EGF). First, we 
showed, by conducting experiments at different time intervals, that both hypoxia and 
EGF stimulation lead to an increase in the expression of HIF-1α and VEGF. Then, the 
time point with the highest VEGF expression was used to carry out the remaining 
experiments in order to identify the players behind VEGF production in these cells. The 
knockdown of the Rho GTPases, RhoA and RhoC separately had no effect on VEGF 
expression neither after hypoxia nor after EGF stimulation. However, when both RhoA 
and RhoC were knocked down, VEGF expression decreased after EGF stimulation. 
Moreover, when the astrocytoma cells were subjected to hypoxia at different times, we 
detected a significant increase in pERK. So, in order to confirm that the MAPK pathway 
is involved in VEGF expression, we added the MAPK inhibitor U0126 to these cells. 
U0126 resulted in a decrease in VEGF expression in the EGF stimulated cells as well as 
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in the hypoxic cells. Therefore, our results show that RhoA and RhoC, as well as the 
MAPK pathway are involved in VEGF production downstream from the EGF receptor 
whereas only the MAPK pathway is involved in VEGF production under hypoxic 
conditions. 
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Chapter One 
Introduction (Literature Background) 
1.1 Cancer: Types, Characteristics and Causes 
    Cancer is a genetic disease characterized by the loss of control over the cell cycle. As 
a result of genetic aberrations, the mutated cells divide uncontrollably and acquire have 
the ability to invade other areas of the body through the blood and lymph (Cooper, 
2000). The genetic alterations may be inherited and/or sporadic. These alterations lead 
to the formation of tumors. However, not all tumors are cancerous. Benign tumors, 
noncancerous, do not have the ability to invade other body areas. On the contrary, 
malignant tumors are "cancerous” and are able invade other body areas (Cooper, 2000). 
Cancer is among the leading causes of death worldwide; 8.2 million Cancer related 
deaths were reported in 2012. Most common cancer mortalities are cancers of the lung, 
liver, stomach, colorectal, breast and esophageal cancer (“WHO | Cancer,” 2015). 
    Cancer develops from any proliferating cell in the body through a multistage process. 
There are more than a hundred different types of cancers but are classified into 
categories based on the cell, tissue or organ the cancer cells originate from (Table 1) 
(“National Cancer Institute,” 2015). 
Table 1: The main categories of cancer and the origin of each 
Category Cancer cell origin 
Carcinoma Epithelial tissues 
Sarcoma Connective tissues 
Leukemia Blood forming tissues 
Lymphoma Lymphocytes (B or T) 
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Myeloma Myeloma cells 
Melanoma Melanocytes 
Brain and Spinal cord cancers Nervous tissues 
 
Cancer cells share common characteristics known as the “Hallmarks of Cancer” which 
are shown in figure 1. These hallmarks comprise the ability of cancer cell to divide 
uncontrollably through self-sustained growth signals, ability to invade other areas of the 
body through the blood and lymph (metastasis), ability to cause the development of new 
blood vessels to maintain the supply nutrients and oxygen (angiogenesis), ability to 
evade apoptosis (programmed cell death), growth suppressor signals and contact 
inhibition thus forming tumors (Hanahan & Weinberg, 2011). 
 
Figure 1:The Hallmarks of Cancer (Hanahan & Weinberg, 2011) 
 
    Many factors may lead a normal cell to change into a cancer cell. These may be: 
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Physical (ionizing and ultraviolet radiations), chemical (tobacco smoke, alcohol, food 
and water contaminants) and/or biological (viruses and other pathogens). All these 
carcinogenic factors, among other factors (like aging) interact with cells at a genetic 
level affecting tumor suppressor genes and/or proto-oncogenes (“WHO | Cancer,” 
2015). Tumor suppressor genes and proto-oncogenes are two broad families of genes 
that play a role in regulating cell division. When these genes are mutated, cells divide 
uncontrollably and cancer develops.  
    Tumor suppressor genes, like TP53 gene, are genes that normally stop or slow down 
cell division to help repair damages in the DNA. These genes also favor apoptosis if the 
damage cannot be repaired. Mutations affecting tumor suppressor genes may cause them 
to be permanently deactivated (turned off). As a result, cells cannot be ordered to stop 
division and cancer develops (“American Cancer Society,” 2014) 
    Proto-oncogenes, like KRAS gene, are genes that normally cause cells to divide and 
inhibit apoptosis. Mutations in these genes may cause them to become permanently 
activated (turned on). In this case, these genes become known as the cancer causing 
genes, oncogenes, that lead to the development of cancer (“American Cancer Society,” 
2014). 
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1.2 Brain Tumors 
    A brain tumor is an abnormal mass of cells that developed from the uncontrollable 
division of non-typical cells in the tissues of the brain. Numerous factors, from genetic 
to environmental factors play an important role in the development of such tumors. 
1.2.1 Astrocytoma 
    Astrocytomas are abnormal growths in the CNS which have derived from astrocytes 
(Kennedy, 2016). These tumors can develop in different parts of the nervous system 
ranging from the cerebrum to the brain stem and spinal cord (“American Brain Tumor 
Association,” 2014). Depending on the tumor’s innate characteristics and invasiveness, 
patients with astrocytoma may survive from less than a year up to 10 years and based on 
their invasive capabilities, astrocytic tumors have been categorized into two classes: 
Those with narrow zones of infiltration (low grade astrocytoma) e.g. pilocytic 
astrocytoma, and those with diffuse zones of infiltration (high grade astrocytoma) e.g. 
glioblastoma (Kennedy, 2016).  
1.2.1.1 Astrocytoma grading schemes 
Several grading systems have been developed to assign the tumor to a specific grade 
after histological examination of a biopsy or specimen. The part of tumor with the most 
anaplasia (poor cellular differentiation) is used to assign a grade for the tumor. Such 
systems include (Kennedy, 2016): 
 Baily and Cushing grading system 
 Kernohan grades I-IV 
 World Health Organization (WHO) grades I-IV 
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 St. Anne/Mayo grades 1-4 
 
1.2.1.2 WHO grading system 
This is a four- grade- four- edition grading system whose first edition dates back to 1979 
and last edition to 2016. Like the pervious editions, the latest edition assigns the 
astrocytoma tumors in one of the four grades. However the latest edition, uses for the 
first time molecular parameters (IDH mutant, H3 K27M mutant, RELA fusion-positive, 
C19MC-altered) in addition to the other usual histological parameters, thus providing a 
notion for how astrocytoma should be classified in the molecular era.   
The WHO scale is as follows (Figure 2) (Furnari et al., 2007; Kennedy, 2016; Louis et 
al., 2016): 
 Grade I: Assigned to nonmalignant astrocytomas that are surgically removed 
(Pilocytic astrocytoma). 
 Grade II: Assigned to moderately proliferative, low grade malignant 
astrocytomas that can be surgically removed if the cells didn’t yet infiltrate to 
other areas of the brain (Diffuse astrocytoma). 
 Grade III: Assigned to astrocytomas with less differentiation and more 
proliferation than that of grade II. These brain tumors are more rapidly lethal 
(Anaphylactic astrocytoma). 
 Grade IV: Are assigned to astrocytomas that display high proliferative and 
metastatic characteristics as well as angiogenesis and treatment defiance. These 
tumors are generally fatal within a year (Glioblastoma).  
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                   Figure 2: Relationship between pathobiology, survival, and mutations which lead to the   
                  development of grade IV glioblastoma either progressively or de novo (Furnari et al., 2007). 
 
1.3 Angiogenesis 
Angiogenesis, the fabrication of neo-blood vessels (capillaries) from pre-existing ones, 
is an essential process required for many physiological processes such as wound healing 
and menstrual cycle, and is also behind many pathological processes which result from 
either excessive or insufficient angiogenesis (Figure 3) (Bisht, Dhasmana, & Bist, 2010; 
Maeshima, 2007). Angiogenesis is different from vasculogenesis. Vasculogenesis is the 
formation of blood vessels during embryonic life from ancestral endothelial cells (ECs) 
while angiogenesis is a multiplex, highly controlled biological phenomenon that requires 
branching and remodeling of pre-existing vasculatures (Bisht et al., 2010). 
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In spite of surgeries and different therapies, brain tumors remain fatal. Their malignant 
phenotype, progress, morbidity and mortality rely on angiogenesis which is initiated by 
the release of the vascular endothelial growth factor (VEGF) by these tumor cells (Jain 
et al., 2007). Not only these newly formed blood vessels supply the tumor cells with 
nutrients and oxygen which are necessary for their survival and growth but also 
contribute to an averse microenvironment characterized by low oxygen tension and high 
interstitial fluid pressure that account for a more malignant phenotype (Jain et al., 2007).  
 
 
Figure 3: Examples of angiogenesis related diseases (Cao, 2010) 
The process of angiogenesis in cancer takes place in four major highly coordinated steps 
(Figure 4): 
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1. Commencement  of the angiogenic process 
2. The breakdown of the basement membrane by proteases 
3. Endothelial tube evolution 
4. Maturation of the newly formed blood vessels/sprouts 
 
Commencement of the angiogenic process: 
Whether in physiological or pathological conditions, the major goal behind this step is 
the activation of ECs. ECs activation comes after a drop in the amount of oxygen 
reaching the tissues: Hypoxia. The latter causes a rise in the hypoxia inducible factor 
(HIF) which leads to the release of proangiogenic factors that activate ECs (Bisht et al., 
2010). 
Breakdown of the basement membrane by proteases: 
This step is an essential preparatory step for endothelial tube evolution since it allows 
the movement and multiplication of ECs in the interstitium (Maeshima, 2007). This step 
is manifested by the release of proteases from ECs which lead to the degradation of the 
basement membrane as seen in figure 4. Such proteases include matrix metalloproteases 
(MMPs), catheprins and plasminogen activators (PAs) (Bisht et al., 2010). 
Endothelial tube evolution: 
The breakdown of the basement membrane results in an increase in the concentration of 
many growth factors and paves the way for a “leader” EC which is accompanied by 
additional ECs to migrate and multiply in the interstitium forming endothelial tubes as 
seen in figure 4 (Ausprunk & Folkman, 1977). Growth factors such as vascular 
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endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and platelet-
derived growth factor (PDGF) play a major role in the migration and multiplication of 
ECs (Bisht et al., 2010). 
Maturation of the newly formed blood vessels/sprouts: 
This is the final step of angiogenesis which is characterized by the formation of the 
vascular basement membrane and by the recruitment of mesenchymal cells, pericytes 
and smooth muscle cells to the wall of the sprout. This step is necessary for the ECs to 
acquire their polarity forming the capillary’s lumen and is also important for the stability 
of the newly formed capillary as shown in figure 4 (Bisht et al., 2010; Maeshima, 2007) 
 
Figure 4: Key events involved in the process of angiogenesis (Lowe et al., 1995) 
1.4 Angiogenic Modulators 
Angiogenesis is a multistep process that requires a delicate balance between 
proangiogenic (positive regulators) and antiangiogenic factors (negative regulators) 
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(table 2). The switch from an angiogenic to a non-angiogenic phenotype relies on a 
change in the balance between these factors (Hoeben et al., 2004). 
Table 2: Major positive and negative regulators of angiogenesis (Bisht et al., 2010) 
Positive regulators Negative regulators 
VEGF                                                       
PDGF-BB 
bFGF                                                           
Midkine 
P1GF                                                           
EGF 
G-CSF                                                          
TGFα,β 
HGF                                                          
Follistatin  
Angiopoietin-1/2                                      IL-3, 
8 
PD-ECGF                                                     
TNF-α 
Angiogenin                                                
Proliferin 
INF-α, β, γ                                           
Angioarrestin 
PF4                                                         
Troponin-1 
Prolactin 16D frag.                               IL-4, 
10, 12 
Angiostatin                                            PEDF 
Endostatin                                             MIG 
Vasostatin                                             TIMP 
Arresten                                                 PAI 
Tumstatin                                           Meth-1, 2 
VEGF 
VEGF is a family of signaling proteins consisting of seven members all sharing a VEGF 
homology domain. The VEGF family includes VEGF-A, VEGF-B, VEGF-C, VEGF-D, 
VEGF-E, VEGF-F and P1GF (Hoeben et al., 2004). VEGF-A is referred to as VEGF 
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due to its essential role in promoting angiogenesis and vascular permeability under both 
normal and pathological conditions. The inactivation of one of the VEGF-A alleles in 
mice leads to embryonic mortality due to flawed blood vessel formation (Maeshima, 
2007). VEGF acts as a powerful mitogen to EC in vitro, as a strong inducer to 
neovascularization in vivo and may also have an autocrine stimulatory effect on cancer 
cells (Figure 5) (Maeshima, 2007; McMahon, 2000).  
There are at least 7 isoforms of VEGF-A coded for by one VEGF-A gene via alternative 
splicing (Hoeben et al., 2004). The transcription of VEGF-A gene is upregulated in 
response to hypoxic conditions by HIF-1. The latter also renders stability to the VEGF-
A transcript, lengthening its translation time. Also, the levels of VEGF-A mRNA 
increases in response to growth factors (like TGF-α, TGF-β, etc...) and cytokines (like 
IL-1α and IL-6). 
 
           Figure 5: Paracrine and autocrine stimulation by positive angiogenic regulators (McMahon, 2000) 
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VEGF-A binds to tyrosine kinase transmembrane receptors: VEGFR-1 and VEGFR-2 
(Figure 6). Upon its binding, these receptors dimerize and intrinsic phosphorylation of 
the cytoplasmic tyrosine residues takes place generating a proangiogenic signal 
(McMahon, 2000). This proangiogenic signal is mainly due to VEGFR-2 because of its 
tyrosine kinase activity is much stronger than VEGFR-1. After its trans-
phosphorylation, VEGFR-2 (exclusively expressed on endothelial cells) leads to the 
activation of PLC ϒ-PKC-MAPK pathway which is essential for ECs’ migration and 
multiplication  (Hoeben et al., 2004; McMahon, 2000; Muñoz-Chápuli, Quesada, & 
Angel Medina, 2004; Shibuya, 2011) 
 
Figure 6: Different VEGF family components and their corresponding receptors (Shibuya, 2011) 
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1.5 Stimulants of angiogenesis inducers in cancer cells 
1.5.1 EGF 
The epidermal growth factor (EGF) is the founding member of the EGF protein 
superfamily. The members of the EGF superfamily are coded by separate genes but all 
share a common consensus sequence known as the EGF motif which is essential for the 
EGF superfamily members to bind to their receptor: Epidermal growth factor receptor 
(EGFR) (Carpenter & Cohen, 1990; Dreux, Lamb, Modjtahedi, & Ferns, 2006)  
After its synthesis, EGF is in an immature form until it is proteolytically cleaved into a 
53 amino acid peptide capable of binding to the transmembrane receptor tyrosine kinase 
EGFR (“Gene NCBI,” 2016; Herbst, 2004). The binding of EGF to EGFR leads to the 
receptor’s dimerization and trans-auto-phosphorylation of the tyrosine residues present 
on the COOH terminal of the cytoplasmic side of the receptor (Alberts et al., 2002; 
Scaltriti & Baselga, 2006)(Figure 7). Once phosphorylated, these tyrosine residues 
enable the binding  of proteins with Src homology 2 and phosphotyrosine binding 
domains leading to the activation of downstream signaling pathways involved in 
angiogenesis, survival, growth and motility (Figure 8) (Alberts et al., 2002; Herbst, 
2004; Scaltriti & Baselga, 2006). 
As for EGF’s role in angiogenesis, it has been well documented that in certain cancer 
cell lines like epidermal carcinoma (Petit et al., 1997), breast cancer (Peng et al., 2006), 
and some glioblastoma (Scaltriti & Baselga, 2006), EGF leads to an increase in 
production and secretion of VEGF. In addition, Peng et al showed that under normoxic 
conditions the EGF-EGFR signaling pathway leads to an increase in the levels of HIF-
1α. Normally, HIF-1α increases under hypoxic conditions to produce along with the  
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Figure 7: Dimerization and cross-phosphorylation of a tyrosine kinase receptor upon the binding of a signaling 
molecule like EGF (Alberts et al., 2002) 
 
 
Figure 8: EGFR activation by EGF and the downstream pathways involved affecting motility, angiogenesis and 
growth (Herbst, 2004). 
constitutively expressed HIF-1β (also known as ARNT) the transcription factor hypoxia 
inducible factor 1 (HIF1) (Wilkins, Abboud, Hancock, & Schofield, 2016). HIF1 is 
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behind the transcription of several genes responsible for survival and angiogenesis 
including VEGF. 
1.5.2 Hypoxia 
All eukaryotes are dependent on oxygen in order to produce adenosine triphosphate 
(ATP) by aerobic respiration. The ATP produced is essential for normal cellular 
functions, tissue development and maintenance of a constant internal environment 
(Krock, Skuli, & Simon, 2011). In mammals, oxygen is delivered to the cells by the 
cardiovascular system; this is why this system is the first system that forms during 
embryonic development. The formation of the cardiovascular system is dependent on 
the formation of the prime blood vessels (vasculogenesis) and the formation of neo-
blood vessels from pre-existing ones (angiogenesis). The first process occurs during 
embryonic development while the second occurs during embryonic and adults lives 
(Zimna & Kurpisz, 2015). Both processes are coordinated with the oxygen supply; high 
proliferation requires high oxygen supply. Therefore, oxygen acts a molecular stimulus. 
Its availability determines if angiogenesis will occur or not. 
Tumor cells continuous proliferation causes them to grow past the oxygen diffusion 
range and as a result these cells become in a state of hypoxia (Chen, Endler, & 
Shibasaki, 2009). In response to the drop in oxygen tension, hypoxia inducible factors 
(HIFs), main hypoxia detectors, are upregulated. HIFs are transcription factors that lead 
to the transcription of many genes that are essential for cell proliferation, survival, 
glucose metabolism, adaptation to pH, migration, invasion (Krock et al., 2011). VEGF, 
as mentioned in section 1.4.1, is the principle angiogenic modulator. In hypoxic 
conditions VEGF is released from the tumor cells and binds to its receptors on ECs. 
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Once this happens, the formerly inactive cells become active and eventually undergo 
angiogenesis with the guidance of VEGF and other angiogenic modulators. VEGF 
expression is under direct control of HIFs’ HIF1α and HIF2α (Chen et al., 2009; 
Chouaib et al., 2012; Krock et al., 2011; Zimna & Kurpisz, 2015). Thus, hypoxia is a 
major angiogenic stimulant. 
1.6 Signaling pathways regulating angiogenesis  
1.6.1 PI3K pathway  
Phosphatidylinositol 3- kinases (PI3K) are a family of lipid kinases that transfer a 
phosphate group to the 3’OH of the inositol ring of phosphatidylinositol. Based on their 
process of activation, phosphorylated substrates, location, number of substrates and role, 
mammalian PI3K family branches into 3 classes: I, II and III (B.-H. Jiang & Liu, 2009; 
Karar & Maity, 2011). Class I is further divided into two subclasses: Class IA and class 
IB which are activated by RTKs and G-protein-coupled receptors (GPCRs) respectively 
(Engelman, Luo, & Cantley, 2006). The enzymes of both subclasses are made up of two 
subunits; a catalytic subunit and a regulatory subunit (Karar & Maity, 2011). Class I 
PI3Ks phosphorylate PI, PIP and PIP2 and have a key role in various cellular functions 
like multiplication, motility, metabolism, survival and angiogenesis. These functions are 
mainly manifested through PIP3 that activates PDK1 and AKT that in turn 
phosphorylate mechanistic target of rapamycin (mTOR) (Jean & Kiger, 2014; Karar & 
Maity, 2011). Class II, with a poorly understood role, is divided into 3 subclasses: 
PI3KC2α, PI3KC2β, and PI3KC2ϒ which are activated by RTKs, cytokine receptor and 
integrins. The PI3Ks of class II are made up of only a catalytic subunit that 
phosphorylates PI and PIP. Class III, like class I, are heterodimeric but only 
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phosphorylate PI (Jean & Kiger, 2014; B.-H. Jiang & Liu, 2009). Unlike class I and II 
that are present in multicellular organisms, class III is present in all eukaryotes and was 
first discovered in yeasts (Herman & Emr, 1990). Class III PI3Ks play a role in cell 
membrane localization, endocytosis and autophagy (Jean & Kiger, 2014; B.-H. Jiang & 
Liu, 2009). 
Angiogenesis is promoted through the communication among cancer cells and ECs in 
the tumor’s microenvironment. PI3K pathway plays a key role in mediating this process 
by influencing the increased production and release of angiogenic promoters such as 
VEGF and also down regulating angiogenic inhibitors. The increased VEGF secretion in 
turn activates the PI3K pathway in EC leading to their activation and increased vascular 
permeability (B.-H. Jiang & Liu, 2009). The PI3K pathway and VEGF production in 
cancer cells is activated through growth factors or hypoxia in a HIF dependent (B. H. 
Jiang et al., 2001; Peng et al., 2006; Zhong et al., 2000)(Mazure, Chen, Laderoute, & 
Giaccia, 1997; Xue et al., 2006) or independent manner (Mizukami et al., 2006). The 
binding of growth factors like EGF activates EGFR that leads to the activation of PI3K 
which phosphorylates protein kinase B (AKT). AKT activation leads to mTOR 
activation which leads to an increase in HIF-1α that leads to an increase in VEGF 
production (Figure 9) (Karar & Maity, 2011). On the other hand, hypoxia may lead to an 
increase in HIF or leads to PI3K activation through Kristen rat sarcoma (K-RAS). PI3K 
then leads to the activation of rho that activates rho associated protein kinase (ROCK) 
that in turn activates c-Myc that binds to Myc-Max-binding element leading to an 
increase in VEGF (Figure 10) (Mizukami et al., 2006). 
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Figure 9: PI3K pathway in angiogenesis (Karar & Maity, 2011, p. 3) 
 
Figure 10: PI3K pathway leading to an increased production of VEGF after hypoxia in a HIF1 independent 
manner (Mizukami et al., 2006) 
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Also, it has been well documented that in certain cancer cells, the presence of STAT3 
and HIF-1α on the VEGF promoter greatly increase VEGF expression and that STAT3 
is essential for HIF-1α-PI3K mediated expression. The use of PI3K inhibitor prevents 
the binding of STAT3 to VEGF promoter and prevents HIF1 expression (Cascio et al., 
2009; Gray et al., 2005). 
In addition to hypoxia and growth factors, VEGF expression through PI3K-HIF-1α can 
also be mediated by constitutively inactive phosphate and tensin homolog (PTEN) 
(Zundel et al., 2000). PTEN is a phosphatase that dephosphorylates PIP3 into PIP2 thus 
stopping the PI3K pathway. Mutations affecting PTEN’s activity lead to the 
development of many cancers (Chu & Tarnawski, 2004). 
1.6.2 The MAPK pathway: 
MAPK is an exclusive eukaryotic kinase enzyme that phosphorylates the OH group of 
serine and threonine of various substrates that may be cytoplasmic or nuclear (Roskoski, 
2012). MAPK is activated upon its phosphorylation in a 3 step process known as “the 
three tiered cascade”. The latter is initiated by the activation of plasma membrane 
receptors in response to various stimuli like cytokines, growth factors and 
neurotransmitters. In this cascade, MAPK is activated through phosphorylation by 
MAPKK that had been previously activated via phosphorylation by MAPKKK 
(Figure11) (Orton et al., 2005). 
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Figure 11: Activation of MAPK by via “the three tiered cascade” (Orton et al., 2005) 
There are at least 8 MAPKs, 7 MAPKKs and 12 MAPKKKs in eukaryotic cells. 
MAPKKK is typically activated through a small GTPase, like Ras, that has been 
activated by signaling complexes bound to the activated membrane receptors: Tyrosine 
kinases, G coupled receptors or integrins (Orton et al., 2005).  
As for its effect on VEGF expression, it has been well reported that MAPK pathway has 
an essential role in upregulating VEGF in many cancer cells (Masoud & Li, 2015). Jae-
moon et al reported that cervical carcinoma cells treated with melittin show a decrease 
in HIF-1α/VEGF expression via ERK and mTOR inhibition following EGF stimulation 
(Shin et al., 2013). In addition, several studies have shown the influence of MAPK 
pathway in upregulating HIF-1α which is well known to increase VEGF expression 
(Masoud & Li, 2015). These studies suggest that certain growth factors lead to the 
activation of the Ras/Raf/MEK/ERK pathway which leads to the phosphorylation of 
many proteins like MNK and CBP/30 which lead to an increase in angiogenic promoters 
including VEGF through HIF-1α (Du et al., 2011; Masoud & Li, 2015; Orton et al., 
2005; Sang et al., 2003). 
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1.7 Aim of this study 
As mentioned previously, when faced in hypoxic conditions, cancer cells secrete many 
positive angiogenic regulators. The most famous one is VEGF. The released VEGF 
binds to its receptors on the nearby endothelial cells activating them and causing them to 
develop new capillaries supplying the tumor cells with the nutrients and oxygen needed 
by these cells to survive, proliferate and invade other body areas. The released positive 
angiogenic regulators not only have a paracrine activity on the endothelial cells but also 
an autocrine activity on the cancer cells themselves, enhancing their survival and 
influencing the release of positive angiogenic regulators. On a different note, our lab has 
studied the pathways and different factors affecting angiogenesis at the level of 
endothelial cells. These studies showed an important role played by the RhoGTPases, 
the PI3K pathway, DLC2, ROCK1/2, and STARD13. Therefore, and as a resulted of the 
previously mentioned literature background and the previous work done in our lab, in 
this study, we want to shed light on cancer cells, SF268, and their ability to induce 
angiogenesis in response to hypoxia and to growth factor stimulation through the 
production and release of VEGF. As a result, this study aims to investigate the different 
pathways and proteins involved in the production of VEGF in SF268, whether it differs 
if these cells were stimulated by EGF or subjected to hypoxia and whether the 
RhoGTPases are also involved in angiogenesis, this time in cancer cells, through the 
production of VEGF. The plan summarizing the aim of this study and the factors 
involved in angiogenesis in ECs are shown in figure 12. 
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Figure 12: Plan showing the aim of the study at one hand (left) and the pathway involved in angiogenesis in EC 
as discovered by El Sibai et al on the other hand (right) (El Sibai et al., 2015).  
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 Chapter Two 
 Materials and Methods 
2.1 Cells and Culture Conditions 
    The cells cultured in the present study were the human adult glioblastoma cell line 
(grade IV) SF268. These cells were cultured in Dulbecco`s Modified Eagle Medium 
(DMEM) supplemented with 10% Fetal Bovine Serum (FBS) and 100U/µl of 
penicillin/streptomycin at 37ºC and 5% CO2. 
2.2 EGF Stimulation 
    SF268 cells with 80% confluency were plated in 6-well plates overnight. The cells 
were then washed with 2mls of PBS (1X) and then starved for 3 hours with 0.1% BSA 
in GIBCO Leibovitz`s L-15 Medium (1X) Liquid obtained from Invitrogen at 37ºC in an 
incubator. After 3 the hours, under the laminar flow hood the cells were washed directly 
with PBS (1X) and stimulated with 15nM of recombinant human epidermal growth 
factor (EGF) obtained from Invitrogen for specific time intervals. Finally, after finishing 
with the time stimulations, the cells were washed with ice cold PBS (1X) and plates 
were transferred on ice for protein extraction.  
 
2.3 Hypoxic Exposure 
    SF268 cells of 80% confluency were plated in 6-well plates overnight. In order to 
attain hypoxic conditions, cobalt (II) chloride hexahydrate (CoCl2) was added to the 
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cultured cells at a final concentration of 200µM for an appropriate time. Finally, after 
the hypoxic exposure, the cells were washed with ice cold PBS (1X) and plates were 
transferred on ice for protein extraction.  
 
2.4 Cell Transfection and Small Interfering RNA (siRNA) 
    Human FlexiTubesiRNA for RhoA (oligo-1 and oligo-6) and RhoC (oligo-5 and 
oligo-6) were obtained from Qiagen (Qiagen, US). Each siRNA had a specific target 
sequence; siRhoA had a target sequence of NM_001664. siRhoC had a target sequence 
of NM_001042678, NM_00104269 and NM_175744. The SF-268 cells were transfected 
with the siRNA at a final concentration of 20µM using a HiPerfect Transfection 
Reagents obtained from Qiagen (Qiagen, US) as mentioned by the manufacturer. After 
72 hours, the protein levels in total cell lysates were analyzed by western blotting using 
the appropriate antibodies. 
 
2.5 Inhibitor Treatments 
    In some experiments, U0126 and wortmannin (Wort), selective pharmacological 
inhibitors of ERK and PI3K respectively, were added to the cells before exposure to 
hypoxia or EGF stimulation. U0126 was added to the cultured cells at a final 
concentration of 50µM for 48 hours while Wort was added at a final concentration of 
100nM for 20 minutes.  
25 
 
2.6 Western Blot Analysis 
         The whole cell lysates were prepared by scraping the cells with Laemmli Sample 
Buffer (LSB) containing 4% SDS, 20% Glycerol, 10% β-Mercaptoethanol, 0.004% 
Bromophenol Blue and 0.125M Tris-HCl (pH=6.8). The SDS-PAGE was performed 
under standard and optimized conditions and the proteins were blotted or transferred 
onto a PVDF membrane. Membranes were then blocked either by 5% fat free milk or 
5% BSA for 1 hour at room temperature and incubated overnight with primary antibody 
against VEGF (Santa Cruz Biotechnology Inc., Europe and Abcam Inc, Cambridge, UK) 
(1:1000 dilution), or against RhoA (Santa Cruz Biotechnology Inc., Europe) (1:500 
dilution), or against RhoC (Abcam Inc, Cambridge, UK) (1:500 dilution), or against 
pan-Akt (Abcam Inc, Cambridge, UK) (1:500 dilution), or against Akt1 phosphorylated 
at T308 (Abcam Inc, Cambridge, UK) (1:1000 dilution), or against ERK (Abcam Inc, 
Cambridge, UK) (1:10000 dilution), or against Anti-Erk1 (pT202/pY204) + Erk2 
(pT185/pY187) (Abcam Inc, Cambridge, UK) (1:500 dilution), or against HIF1α 
(Abcam Inc, Cambridge, UK) (1:100 dilution), or against actin (Santa Cruz 
Biotechnology Inc., Europe and Abcam Inc, Cambridge, UK) (1:1000). After that, the 
membranes were washed 6 times, 5 minute interval each, with Tris-buffered saline-0.1% 
Tween 20 (TBST) at room temperature. The membranes were then incubated with 
secondary antibodies (1:10000 or 1:5000 dilutions) for 1 hour at room temperature. 
Blots were developed using chemi-luminescent reagent ECL detection kit (GE 
Healthcare). The results were obtained on an X-ray film (Agfa, Healthcare). The levels 
of expression of proteins were compared by densitometry using the ImageJ software and 
plotted in Excel.  
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2.7 Statistical Analysis 
    All the results reported represent average values from two independent experiments. 
All error estimates are given as the mean ± standard error of the mean (S.E.M). 
Statistical differences were determined using one-way analysis of variance. P values less 
than 0.05 were considered significant.  
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 Chapter Three 
 Results 
3.1 Hypoxia Induction 
    In order to determine if the system we have set up to induce hypoxia through CoCl2  
is efficient, we checked, through western blot, the level of expression of HIF1α at 
different time intervals up to 24 hours after the addition of CoCl2 to the cultured cells. 
The results are shown in figure 13. HIF1α level of expression showed a significant 
increase with p-values < 0.05 as the hypoxic time conditions increased from 0 hours to 
24.
 
Figure 13:  Ratio of HIF1α/β-actin in total cell lysates at different time intervals after the exposure to hypoxia 
for 24 hours. (A) Showing the quantified western blot results of (B). β-actin expression was used as a control for 
protein loading and blotting. Representative experiment out of 2 is shown. p-value <0.05 
* 
* 
* * 
* 
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3.2 Effect of hypoxia on the expression level of VEGF 
    To verify the literature’s documentations that hypoxia leads to an increase in VEGF 
expression, the SF268 cells were subjected to hypoxia up to 24 hours and the level of 
VEGF was studied at different time intervals. The results are shown in figure 14. VEGF 
expression showed a significant increase by 1.7 folds at 4 after hypoxia.  
 
Figure 14: Ratio of VEGF/β-actin in total cell lysates at different time intervals after the exposure to hypoxia 
for 24 hours. (A) Showing the quantified western blot results shown in (B). β-actin expression was used as a control 
for protein loading and blotting. Representative experiment out of 2 is shown. p-value at 4 hours: 0.015 
3.3 Regulators of VEGF expression in response to hypoxia 
    In order to identify which pathways are involved in hypoxic conditions and thus 
might potentially affect VEGF expression, the expression levels of pAKT, PIP3, pERK, 
RhoA and RhoC were studied at different times through western blot during a 24 hour 
hypoxic conditions. 
3.3.1 The PI3K pathway 
A- Is PI3K activated in response to hypoxia?  
* 
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    In order to check if PI3K pathway involved in the regulation of VEGF expression 
under hypoxic conditions, we checked at different time intervals and within a 24 hour of 
hypoxic conditions for the phosphorylation of AKT and increase in PIP3 which would 
reflect the activation of PI3K. The results are shown in figures 15 and 16. AKT 
phosphorylation decreased approximately by 2.2 folds and PIP3 expression decreased by 
2 folds within the 24 hour hypoxic conditions. 
 
 
Figure 15: Ratio of pAKT/AKT in total cell lysates at different time intervals after the exposure to hypoxia for 
24 hours. (A) Showing the quantified western blot results shown in (B). Pan-AKT expression was used as a control 
for protein loading and blotting. Representative experiment out of 2 is shown. p-values <0.05 
* * 
* * 
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Figure 16: Ratio of PIP3/β-actin in total cell lysates at different time intervals after the exposure to hypoxia for 
24 hours. (A) Showing the quantified western blot results shown in (B). β-actin expression was used as a control for 
protein loading and blotting. Representative experiment n=1 is shown. 
 
B- Effect of PI3K inhibition on VEGF expression after hypoxia 
The results demonstrated by figures 15 and 16 reflect, at least, that PI3K pathway is not 
stimulated in response to hypoxia. In order to rule out its involvement in regulating VEGF 
expression in response to hypoxia we directly used wortmannin to inhibit PI3K. 
However, first, and in order to determine the time in which wortmannin is most 
effective, we checked at different time intervals, through western blot, the change in the 
level of phosphorylation of pAKT after wortmannin was applied to the SF268 cells at a 
final concentration of 100nM. The results are shown in figure 17. The expression of 
pAKT decreased till it reached 0 as the time of wortmannin treatment increased to 16 
minutes. 
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Figure 17: Ratio of pAKT/AKT in total cell lysates at different time intervals after the addition of wortmannin 
for 30 minutes. (A) Showing the quantified western blot results shown in (B). Pan-AKT expression was used as a 
control for protein loading and blotting. Representative experiment out of 2 is shown. p-values <0.05 
After determining the time in which wortmannin is effective, the SF268 cells were 
treated with wortmannin for 20 minutes and then were subjected to hypoxia for 4 hours 
in order to confirm, through western blot, that PI3K is not involved VEGF expression. 
The results are shown in figure 18. There was no significant change in VEGF expression 
upon PI3K inhibition by wortmannin. 
* 
* 
* 
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Figure 18: Ratio of VEGF/β-actin in total cell lysates 6 hours after hypoxia. The latter was preceded by the 
addition of wortmannin for 20 minutes. (A) Showing the quantified western blot results shown in (B). β-actin 
expression was used as a control for protein loading and blotting. Representative experiment n=1 is shown. 
  
3.3.2 The MAPK pathway 
A- Is ERK activated in response to hypoxia 
    In order to investigate if the MAPK pathway is upregulated in hypoxic conditions, we 
checked, through western blot, for the phosphorylation levels of ERK at different time 
intervals during a 24 hour hypoxic conditions. The results are shown in figure 19. ERK 
phosphorylation showed a biphasic pattern of activation, increasing at 4 hours and then 
24 hours by approximately 2.2 folds after hypoxia. This biphasic pattern of activation 
might be due to an autocrine effect of the growth factors released by the cancer cells. 
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Figure 19: Ratio of pERK/ERK in total cell lysates at different time intervals after the exposure to hypoxia for 
24 hours. (A) Showing the quantified western blot results shown in (B). ERK expression was used as a control for 
protein loading and blotting. Representative experiment out of 2 is shown. p-values <0.05 
B- Effect of MAPK inhibition on VEGF expression after hypoxia 
This increase in pERK at 4 hours which coincides with the peak of expression of VEGF 
suggests that the MAPK pathway is involved in the increase in VEGF expression. In order to 
confirm that, we directly inhibited the MAPK pathway by U0126 and looked at the expression 
level of VEGF 4 hours post hypoxia. The results are shown in figure 20. There was a significant 
20% decrease in the VEGF expression. 
  
* 
* 
* 
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Figure 20: Ratio of VEGF/β-actin in total cell lysates 4 hours after hypoxia. The latter was preceded by the 
addition of U0126 for 48 hours. (A) Showing the quantified western blot results shown in (B). β-actin expression 
was used as a control for protein loading and blotting. Representative experiment n=3 is shown. p-value <0.05 
 
3.3.3 The RhoGTPases 
A- What is the effect of hypoxia on RhoA expression? 
    In order to investigate how the expression level of RhoA is affected during hypoxic 
conditions, SF268 cells where subjected to hypoxia for 24 hours and the level of RhoA 
was studied at different time intervals. The results are shown in figure 21. The results 
show a 1.6 fold increase at 4 hours after hypoxia indicating a possible role played by RhoA 
in regulating VEGF expression. 
 
Figure 21: Ratio of RhoA/β-actin in total cell lysates at different time intervals after the exposure to hypoxia 
for 24 hours. (A) Showing the quantified western blot results shown in (B). β-actin expression was used as a control 
for protein loading and blotting. Representative experiment n=1 is shown. 
B- What is the effect of hypoxia on the level of expression of RhoC 
    In order to investigate how the expression level of RhoC is affected during hypoxic 
conditions, the SF268 cells where subjected to a 24 hour hypoxic conditions and the 
level of RhoC was studied by western blotting at different time intervals. The results are 
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shown in figure 22. The expression level of RhoC increased showing approximately a 
1.5 fold increase at 4 and 6 hours after hypoxia indicating a probable role played by 
RhoC in regulating VEGF expression. 
 
Figure 22: Ratio of RhoC/β-actin in total cell lysates at different time intervals after the exposure to hypoxia 
for 24 hours. (A) Showing the quantified western blot results shown in (B). β-actin expression was used as a control 
for protein loading and blotting. Representative experiment n=1 is shown. 
 
C- Effect of RhoA or RhoC knockdown on VEGF expression after hypoxia conditions 
The results of figures 21 and 22 show an increase in RhoA and RhoC expression at 4 hours 
coinciding with VEGF’s peak and thus suggesting their involvement in VEGF expression. In 
order to directly examine their involvement we knocked down RhoA and RhoC separately and 
then looked, through western blot, at the level of VEGF expression 4 hours after hypoxia. 
However, before we studied the effect of RhoA or RhoC knockdown on VEGF expression we 
wanted to confirm that the knockdown is effective. As a result, we performed RhoA and RhoC 
knockdown and then blotted for RhoA and RhoC. The results are shown in figures 23 and 24. 
RhoA showed a 3 fold decrease in both oligos and RhoC decreased by approximately 2 folds 
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indicating that all 4 oligos are effective and can be used to study the effect of RhoA and/or 
RhoC knockdown on VEGF expression.  
 
Figure 17: Ratio of RhoA/β-actin in total cell lysates after RhoA knockdown. (A) Showing the quantified western 
blot results shown in (B). β-actin expression was used as a control for protein loading and blotting. Representative 
experiment n=1 is shown. 
 
Figure 18: Ratio of RhoC/β-actin in total cell lysates after RhoC knockdown. (A) Showing the quantified western 
blot results shown in (B). β-actin expression was used as a control for protein loading and blotting. Representative 
experiment n=1 is shown. 
After confirming that the knockdown is effective, we performed RhoA or RhoC knockdown on 
the SF268 cells and looked the VEGF expression 4 hours post hypoxia. The results are shown in 
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figure 25. No significant change in VEGF expression was recorded. This suggests that the 2 
isoforms might be compensating. Therefore, we moved to doing a double knockdown. 
 
Figure 19: Ratio of VEGF/β-actin in total cell lysates 4 hours after hypoxia. The latter was preceded by RhoA 
or RhoC knockdown. (A) Showing the quantified western blot results shown in (B). β-actin expression was used as a 
control for protein loading and blotting. Representative experiment n=1 is shown 
 
D- VEGF expression in response to hypoxia after RhoA and RhoC double knockdown 
To confirm if the double RhoA and RhoC knockdown is effective, we blotted, using the cell 
lysates that were subjected to the double knockdown, for RhoA and then for RhoC. The results 
are shown in figures 26 and 27. Using RhoA oligo 1 and RhoC oligo 6 showed a 2 fold decrease 
in RhoC and a 5 fold decrease RhoA while using RhoA oligo 6 with RhoC oligo 5 shown a 1.5 
fold decrease in both RhoA and RhoC, indicating that the double knockdown is effective and it 
can be used to determine the effect of both RhoA and RhoC on VEGF expression during 
hypoxia. 
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Figure 20: Ratio of RhoA/β-actin in total cell lysates after RhoA and RhoC double knockdown. (A) Showing the 
quantified western blot results shown in (B). β-actin expression was used as a control for protein loading and blotting. 
Representative experiment n=1 is shown. 
 
Figure 21: Ratio of RhoC/β-actin in total cell lysates after RhoA and RhoC double knockdown. (A) Showing the 
quantified western blot results shown in (B). β-actin expression was used as a control for protein loading and blotting. 
Representative experiment n=1 is shown. 
 
 
After the double knockdown verification, the SF268 cells were subjected to double RhoA 
and RhoC knockdown and then the level of expression of VEGF was determined by 
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western blot 4 hours after hypoxic conditions. The results are shown in figure 28. No 
significant change in VEGF expression was observed suggesting that RhoA and RhoC 
are not involved in VEGF expression in response to hypoxia eventhough their 
expression levels increased in response to hypoxia. 
 
Figure 22: Ratio of VEGF/β-actin in total cell lysates 4 hours after hypoxia. The latter was preceded by RhoA and 
RhoC knockdown. (A) Showing the quantified western blot results shown in (B). β-actin expression was used as a 
control for protein loading and blotting. Representative experiment n=1 is shown 
 
3.4 EGF stimulation of angiogenesis 
In order to verify that the second system we are setting where we stimulate with EGF is 
a proper system, we subjected the SF268 cells to 24 hour EGF stimulation and then we 
checked the level of expression of HIF-1α by western blot. The results are shown in 
figure 29. HIF-1α showed by approximately a 2 fold increase. 
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Figure 23: Ratio of HIF-1α/β-actin 24 hours after EGF stimulation. (A) Showing the quantified western blot 
results shown in (B). β-actin expression was used as a control for protein loading and blotting. Representative 
experiment n=1 is shown. 
3.4.1 Effect of EGF stimulation on VEGF expression 
    To study the effect of EGF stimulation on VEGF expression, the SF268 cells were 
subjected up to 8 hours of EGF stimulations and then the level of VEGF was studied by 
western blot at different time intervals. The results are shown in figure 30. VEGF 
expression showed a 30% increase 4 hours from the EGF stimulation. 
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Figure 24: Ratio of VEGF/β-actin after EGF stimulation. (A) Showing the quantified western blot results shown in 
(B). β-actin expression was used as a control for protein loading and blotting. Representative experiment n=1 is 
shown. 
3.5 Regulators of angiogenesis in response to EGF 
3.5.1 Effect of MAPK inhibition on VEGF expression after EGF stimulation 
To determine if the MAPK pathway is involved in VEGF expression following EGF 
stimulation, the SF268 cells were treated with the MAPK inhibitor U0126 and then were 
subjected to EGF stimulation for 4 hours. Finally, the VEGF expression was determined 
by western blot. The results are shown in figure 31. The VEGF expression significantly 
decreased by 4.4 folds. 
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Figure 25: Ratio of VEGF/β-actin after treatment with U0126 which was followed by a 4 hour EGF 
stimulation. (A) Showing the quantified western blot results shown in (B). β-actin expression was used as a control 
for protein loading and blotting. Representative experiment n=2 is shown. p-value < 0.05 
3.5.2 Effect of RhoA and/or RhoC knockdown on VEGF expression after EGF 
stimulation 
In order to find out if the Rho GTPases RhoA and/or RhoC are involved in VEGF expression 
following EGF stimulation, we performed separate and double RhoA and RhoC 
knockdowns and then studied the VEGF expression by western blot after 4 hours from 
EGF stimulation. The results for the separate RhoA and RhoC knockdowns are shown in 
figure 32 and for the double knockdown are shown in figure 33. No significant change 
was noted upon the separate RhoA and RhoC knockdowns. However, this was not the 
case for the double knockdown where we witnessed a significant 30% decrease in 
VEGF expression.  
 
* 
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Figure 26: Ratio of VEGF expression 4 hours from EGF stimulation after RhoA or RhoC knockdown. (A) 
Showing the quantified western blot results shown in (B). β-actin expression was used as a control for protein loading 
and blotting. Representative experiment n=1 is shown. 
 
Figure 27: Ratio of VEGF/β-actin expression 4 hours from EGF stimulation after RhoA and RhoC double 
knockdown. (A) Showing the quantified western blot results shown in (B). β-actin expression was used as a control 
for protein loading and blotting. Representative experiment n=2 is shown. p-value <0.05 
 
* 
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Figure 34: Diagram showing the pathways and proteins involved in VEGF expression in SF268 cells. 
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 Chapter Four 
 Discussion 
When the cancer cells divide uncontrollably irresponsive to contact inhibition or any 
other suppressive signals, a solid tumor develops (Hanahan & Weinberg, 2011). The 
continuous demand for oxygen by the cells of the solid tumor leads to a drop in the 
oxygen’s partial pressure in the corresponding organ or tissue. To adapt to this new 
stressful condition, the expression level of HIF1 in these tumor cells increases and leads 
to the transcription of various genes that are involved in neo-blood vessel formation and 
in oxygen supply (Wu & Yotnda, 2011). HIF1, a fundamental transcription factor under 
hypoxic conditions, is made up of two components: HIF1-α and ARNT. The latter is 
continuously expressed while HIF1-α only stabilizes under low oxygen tension. When 
HIF1-α is stable, it can bind to ARNT forming HIF1 which in turn will transcribe many 
genes whose protein products are essential to adapt to this new condition (Piret, Mottet, 
Raes, & Michiels, 2002; Wu & Yotnda, 2011). Therefore, the detection of increasing 
quantities of HIF1-α is an indication that cells are in a hypoxic state. In our study CoCl2, 
a chemical inducer of HIF, was chosen to mimic the hypoxic conditions. Figure 13 
shows an increase in HIF1-α after the SF268 cells were treated with CoCl2 for different 
times indicating that we were able to properly induce hypoxia in these cells. Also, 
similar to many literature backgrounds, our results have shown that the stability 
witnessed in HIF1 leads to an increase in expression in the most prominent angiogenic 
positive regulator: VEGF. VEGF expression appeared to be highest 4 hours after 
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hypoxia within a 24 hour time frame of CoCl2 treatment (figure 14). The results shown 
by figures 13 and 14 also indicate that the system we have set up is effective and permits 
us to carry further downstream experiments which will allow us to reveal the factors 
affecting VEGF expression under hypoxic conditions.  
EGF is one of the well-known positive regulators of angiogenesis (Bisht et al., 2010). 
The EGF-EGFR pathway has been associated to many cancer malignant properties, 
from survival and motility to metastasis and angiogenesis (Herbst, 2004). Also, Peng el 
al showed that there is a cross talk between EGFR and HIF1-α in breast cancer cells. 
The information listed before allowed us to hypothesize that EGF might lead to an 
increase in VEGF expression in SF268. This hypothesis was supported by the results 
obtained in figures 29 and 30. The EGF stimulation led to an increase in HIF1-α and 
also to an increase in VEGF expression. These results also allow us to establish another 
proper system that leads to an increase in VEGF expression and consequently enables us 
to study the factors affecting VEGF expression upon EGF stimulation. 
PI3K pathway is an essential pathway needed by the cells for various functions like 
survival, motility and growth. PI3K pathway is well known to be altered in many 
cancers (Vara et al., 2004). Once activated, PI3K phosphorylates PIP2 into PIP3 which 
leads to the phosphorylation of Akt. Once phosphorylated, Akt alters the activity of 
many substrates involved in numerous cancer cell phenotypes. It has been copiously 
reported that EGF stimulation activates PI3K in normal and cancer cells leading to 
different cellular responses like: Wound healing (Tétreault, Chailler, Beaulieu, Rivard, 
& Ménard, 2008), promoting sjogren’s syndrome (Nakamura, Kawakami, Ida, Koji, & 
Eguchi, 2007), telomerase activation (Heeg et al., 2011), cell migration (Duan, Qu, & 
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Shou, 2014) and survival (Peng et al., 2006). On the other hand, PI3K activation has not 
been linked to hypoxia directly but has been shown to play a role in VEGF expression 
under hypoxic conditions (Karar & Maity, 2011; Mazure et al., 1997; Mizukami et al., 
2006; Xue et al., 2006). However, our results have shown that the PI3K pathway is not 
activated under hypoxic conditions; this was demonstrated by the decrease in levels of 
pAKT and PIP3 (figures 15 and 16). In addition, PI3K pathway is not involved in VEGF 
expression during the hypoxic conditions since the SF268 cells showed no change in 
VEGF expression after being treated with wortmannin (figure 18). 
MAPK pathway is another important pathway involved in different cellular functions like cell 
cycle progression, apoptosis prevention and differentiation. It is also found to be altered in many 
cancers (McCubrey et al., 2007). The activation of the pathway starts by binding of a ligand to 
receptor tyrosine kinase e.g. EGFR. When this happens, the receptor dimerizes and eventually 
leads to the activation of Ras. Ras activation leads to the activation of the MAPK that conveys 
the signal from the extracellular environment to transcription factors (McCubrey et al., 2007). 
MAPK signaling was also shown to induce VEGF expression and/ or HIF1-α stabilization and 
angiogenic induction in normal or cancer cells (Du et al., 2011; Hur, Chang, Lee, Lee, & Park, 
2001; Sang et al., 2003; Trisciuoglio, Iervolino, Zupi, & Del Bufalo, 2005; van Golen et al., 2002; 
Wang et al., 2004). In this study, our experiments have shown that MAPK pathway is activated 
in both conditions, EGF stimulation and hypoxia, and is also involved VEGF expression. During 
the hypoxic conditions, the SF268 cells showed an increase in pErk levels indicating the 
activation of the MAPK pathway (figure 19). In addition, a significant decrease in 
VEGF expression was recorded when the hypoxic and EGF stimulated cells were 
previously treated with U0126 (figures 20 and 31), indicating that the MAPK pathway is 
needed for VEGF expression under both conditions. 
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The pathways and factors involved in angiogenesis in ECs were previously studied in 
our lab. The results showed a significant role played by the rhoGTPases RhoA and 
RhoC. The knockdown of RhoA or RhoC in ECs prevented the formation of endothelial 
tubes, thus inhibiting angiogenesis (El Sibai et al, 2015). These findings led us to 
investigate the roles of RhoA and RhoC in the production of VEGF in SF268 cells and 
consequently their role in inducing angiogenesis. RhoA and/or RhoC don’t play a role in 
VEGF expression in SF268 cells under hypoxic conditions since knocking down either 
RhoA or RhoC or knocking down both RhoA and RhoC had no effect on VEGF 
expression (figures 25 and 28). However, RhoA and RhoC play a role in VEGF 
expression and compensate for one another in response to EGF stimulation since 
knocking down either RhoA or RhoC shows no change in VEGF expression (figure 32) 
but knocking down RhoA and RhoC shows a decrease in VEGF expression (figure 33). 
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 Chapter Five 
 Conclusion and Future work 
Our results have shown that VEGF production increases in response to hypoxic 
conditions due to a role played by the MAPK pathway and HIF1α. It also increases upon 
EGF stimulation due to a role played by the MAPK pathway, the Rho-GTPases RhoA 
and RhoC and HIF1α (figure 33). We still need to investigate other players involved in 
response to both conditions, whether the MAPKs are downstream or upstream from the 
Rho-GTPases and whether the listed players are HIF1 independent or not. In addition, 
we are currently studying the factors affecting the VEGF secretion and co-culturing the 
SF268 cells with ECs to directly look at the effect of these factors on angiogenesis 
induction. 
 
 
 
 
 
50 
 
References 
Alberts, B., Johnson, A., Lewis, J., Raff, M., Roberts, K., & Walter, P. (2002). Signaling 
through Enzyme-Linked Cell-Surface Receptors. Retrieved from 
https://www.ncbi.nlm.nih.gov/books/NBK26822/  
American Brain Tumor Association. (2014). Retrieved January 3, 2017, from 
http://www.abta.org/brain-tumor-information/types-of-
tumors/astrocytoma.html 
American Cancer Society. (2014). Retrieved January 3, 2017, from 
http://www.cancer.org/cancer/cancercauses/geneticsandcancer/genesandc
ancer/genes-and-cancer-oncogenes-tumor-suppressor-genes 
Ausprunk, D. H., & Folkman, J. (1977). Migration and proliferation of endothelial cells 
in preformed and newly formed blood vessels during tumor angiogenesis. 
Microvascular Research, 14(1), 53–65. 
Bisht, M., Dhasmana, D. C., & Bist, S. S. (2010). Angiogenesis: Future of 
pharmacological modulation. Indian Journal of Pharmacology, 42(1), 2–
8. https://doi.org/10.4103/0253-7613.62395 
Cao, Y. (2010). Adipose tissue angiogenesis as a therapeutic target for obesity and 
metabolic diseases. Nature Reviews. Drug Discovery, 9(2), 107–115. 
https://doi.org/10.1038/nrd3055 
Carpenter, G., & Cohen, S. (1990). Epidermal growth factor. Journal of Biological 
Chemistry, 265(14), 7709–7712. 
Cascio, S., Ferla, R., D’Andrea, A., Gerbino, A., Bazan, V., Surmacz, E., & Russo, A. 
(2009). Expression of angiogenic regulators, VEGF and leptin, is 
regulated by the EGF/PI3K/STAT3 pathway in colorectal cancer cells. 
Journal of Cellular Physiology, 221(1), 189–194. 
https://doi.org/10.1002/jcp.21843 
Chen, L., Endler, A., & Shibasaki, F. (2009). Hypoxia and angiogenesis: regulation of 
hypoxia-inducible factors via novel binding factors. Experimental & 
Molecular Medicine, 41(12), 849–857. 
https://doi.org/10.3858/emm.2009.41.12.103 
Chouaib, S., Messai, Y., Couve, S., Escudier, B., Hasmim, M., & Noman, M. Z. (2012). 
Hypoxia Promotes Tumor Growth in Linking Angiogenesis to Immune 
Escape. Frontiers in Immunology, 3. 
https://doi.org/10.3389/fimmu.2012.00021 
51 
 
Chu, E. C., & Tarnawski, A. S. (2004). PTEN regulatory functions in tumor suppression 
and cell biology. Medical Science Monitor: International Medical 
Journal of Experimental and Clinical Research, 10(10), RA235-241. 
Cooper, G. M. (2000). The Development and Causes of Cancer. Retrieved from 
https://www.ncbi.nlm.nih.gov/books/NBK9963/ 
Dreux, A. C., Lamb, D. J., Modjtahedi, H., & Ferns, G. A. A. (2006). The epidermal 
growth factor receptors and their family of ligands: their putative role in 
atherogenesis. Atherosclerosis, 186(1), 38–53. 
https://doi.org/10.1016/j.atherosclerosis.2005.06.038 
Du, J., Xu, R., Hu, Z., Tian, Y., Zhu, Y., Gu, L., & Zhou, L. (2011). PI3K and ERK-
Induced Rac1 Activation Mediates Hypoxia-Induced HIF-1α Expression 
in MCF-7 Breast Cancer Cells. PLOS ONE, 6(9), e25213. 
https://doi.org/10.1371/journal.pone.0025213 
Duan, H., Qu, L., & Shou, C. (2014). Activation of EGFR-PI3K-AKT signaling is 
required for Mycoplasma hyorhinis-promoted gastric cancer cell 
migration. Cancer Cell International, 14, 135. 
https://doi.org/10.1186/s12935-014-0135-3 
Engelman, J. A., Luo, J., & Cantley, L. C. (2006). The evolution of phosphatidylinositol 
3-kinases as regulators of growth and metabolism. Nature Reviews. 
Genetics, 7(8), 606–619. https://doi.org/10.1038/nrg1879 
Furnari, F. B., Fenton, T., Bachoo, R. M., Mukasa, A., Stommel, J. M., Stegh, A., … 
Cavenee, W. K. (2007). Malignant astrocytic glioma: genetics, biology, 
and paths to treatment. Genes & Development, 21(21), 2683–2710. 
https://doi.org/10.1101/gad.1596707 
Gene NCBI. (2016). Retrieved January 10, 2017, from 
https://www.ncbi.nlm.nih.gov/gene/1950 
Goldman, C. K., Kim, J., Wong, W. L., King, V., Brock, T., & Gillespie, G. Y. (1993). 
Epidermal growth factor stimulates vascular endothelial growth factor 
production by human malignant glioma cells: a model of glioblastoma 
multiforme pathophysiology. Molecular Biology of the Cell, 4(1), 121–
133. 
Gray, M. J., Zhang, J., Ellis, L. M., Semenza, G. L., Evans, D. B., Watowich, S. S., & 
Gallick, G. E. (2005). HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are 
components of a transcriptional complex that regulates Src-dependent 
hypoxia-induced expression of VEGF in pancreatic and prostate 
carcinomas. Oncogene, 24(19), 3110–3120. 
https://doi.org/10.1038/sj.onc.1208513 
52 
 
Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of Cancer: The Next Generation. 
Cell, 144(5), 646–674. https://doi.org/10.1016/j.cell.2011.02.013 
Heeg, S., Hirt, N., Queisser, A., Schmieg, H., Thaler, M., Kunert, H., … Opitz, O. G. 
(2011). EGFR overexpression induces activation of telomerase via 
PI3K/AKT-mediated phosphorylation and transcriptional regulation 
through Hif1-alpha in a cellular model of oral–esophageal 
carcinogenesis. Cancer Science, 102(2), 351–360. 
https://doi.org/10.1111/j.1349-7006.2010.01796.x 
Herbst, R. S. (2004). Review of epidermal growth factor receptor biology. International 
Journal of Radiation Oncology, Biology, Physics, 59(2 Suppl), 21–26. 
https://doi.org/10.1016/j.ijrobp.2003.11.041 
Herman, P. K., & Emr, S. D. (1990). Characterization of VPS34, a gene required for 
vacuolar protein sorting and vacuole segregation in Saccharomyces 
cerevisiae. Molecular and Cellular Biology, 10(12), 6742–6754. 
Hoeben, A., Landuyt, B., Highley, M. S., Wildiers, H., Oosterom, A. T. V., & Bruijn, E. 
A. D. (2004). Vascular Endothelial Growth Factor and Angiogenesis. 
Pharmacological Reviews, 56(4), 549–580. 
https://doi.org/10.1124/pr.56.4.3 
Hur, E., Chang, K. Y., Lee, E., Lee, S. K., & Park, H. (2001). Mitogen-activated protein 
kinase kinase inhibitor PD98059 blocks the trans-activation but not the 
stabilization or DNA binding ability of hypoxia-inducible factor-1alpha. 
Molecular Pharmacology, 59(5), 1216–1224. 
Jain, R. K., di Tomaso, E., Duda, D. G., Loeffler, J. S., Sorensen, A. G., & Batchelor, T. 
T. (2007). Angiogenesis in brain tumours. Nature Reviews. Neuroscience, 
8(8), 610–622. https://doi.org/10.1038/nrn2175 
Jean, S., & Kiger, A. A. (2014). Classes of phosphoinositide 3-kinases at a glance. 
Journal of Cell Science, 127(5), 923–928. 
https://doi.org/10.1242/jcs.093773 
Jiang, B. H., Jiang, G., Zheng, J. Z., Lu, Z., Hunter, T., & Vogt, P. K. (2001). 
Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-
inducible factor 1. Cell Growth & Differentiation: The Molecular 
Biology Journal of the American Association for Cancer Research, 12(7), 
363–369. 
Jiang, B.-H., & Liu, L.-Z. (2009). PI3K/PTEN signaling in angiogenesis and 
tumorigenesis. Advances in Cancer Research, 102, 19–65. 
https://doi.org/10.1016/S0065-230X(09)02002-8 
53 
 
Karar, J., & Maity, A. (2011). PI3K/AKT/mTOR Pathway in Angiogenesis. Frontiers in 
Molecular Neuroscience, 4, 51. 
https://doi.org/10.3389/fnmol.2011.00051 
Kennedy, B. (2016). Astrocytoma: Practice Essentials, Background, Pathophysiology. 
Retrieved from http://emedicine.medscape.com/article/283453-overview 
Krock, B. L., Skuli, N., & Simon, M. C. (2011). Hypoxia-induced angiogenesis: good 
and evil. Genes & Cancer, 2(12), 1117–1133. 
https://doi.org/10.1177/1947601911423654 
Lartigue, J. (2011). Targeting PI3K/Akt Pathway: 20 Years of Progress. Retrieved 
January 24, 2017, from http://www.onclive.com/publications/oncology-
live/2011/october-2011/targeting-pi3kakt-pathway-20-years-of-progress 
Louis, D. N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., 
Cavenee, W. K., … Ellison, D. W. (2016). The 2016 World Health 
Organization Classification of Tumors of the Central Nervous System: a 
summary. Acta Neuropathologica, 131(6), 803–820. 
https://doi.org/10.1007/s00401-016-1545-1 
Lowe, P. m., Lee, M.-L., Jackson, C. j., To, S. s. t., Cooper, A. j., & Schrieber, L. 
(1995). The endothelium in psoriasis. British Journal of Dermatology, 
132(4), 497–505. https://doi.org/10.1111/j.1365-2133.1995.tb08702.x 
Maeshima, Y. (2007). Angiogenesis and Cancer. In R. Srivastava (Ed.), Apoptosis, Cell 
Signaling, and Human Diseases (pp. 35–61). Humana Press. Retrieved 
from http://link.springer.com/chapter/10.1007/978-1-59745-200-7_2 
Masoud, G. N., & Li, W. (2015). HIF-1α pathway: role, regulation and intervention for 
cancer therapy. Acta Pharmaceutica Sinica. B, 5(5), 378–389. 
https://doi.org/10.1016/j.apsb.2015.05.007 
Mazure, N. M., Chen, E. Y., Laderoute, K. R., & Giaccia, A. J. (1997). Induction of 
vascular endothelial growth factor by hypoxia is modulated by a 
phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-
transformed cells through a hypoxia inducible factor-1 transcriptional 
element. Blood, 90(9), 3322–3331. 
McCubrey, J. A., Steelman, L. S., Chappell, W. H., Abrams, S. L., Wong, E. W. T., 
Chang, F., … Franklin, R. A. (2007). Roles of the Raf/MEK/ERK 
pathway in cell growth, malignant transformation and drug resistance. 
Biochimica Et Biophysica Acta, 1773(8), 1263–1284. 
https://doi.org/10.1016/j.bbamcr.2006.10.001 
McMahon, G. (2000). VEGF receptor signaling in tumor angiogenesis. The Oncologist, 
5 Suppl 1, 3–10. 
54 
 
Mizukami, Y., Fujiki, K., Duerr, E.-M., Gala, M., Jo, W.-S., Zhang, X., & Chung, D. C. 
(2006). Hypoxic regulation of vascular endothelial growth factor through 
the induction of phosphatidylinositol 3-kinase/Rho/ROCK and c-Myc. 
The Journal of Biological Chemistry, 281(20), 13957–13963. 
https://doi.org/10.1074/jbc.M511763200 
Muñoz-Chápuli, R., Quesada, A. R., & Angel Medina, M. (2004). Angiogenesis and 
signal transduction in endothelial cells. Cellular and Molecular Life 
Sciences: CMLS, 61(17), 2224–2243. https://doi.org/10.1007/s00018-
004-4070-7 
Nakamura, H., Kawakami, A., Ida, H., Koji, T., & Eguchi, K. (2007). EGF activates 
PI3K-Akt and NF-kappaB via distinct pathways in salivary epithelial 
cells in Sjögren’s syndrome. Rheumatology International, 28(2), 127–
136. https://doi.org/10.1007/s00296-007-0411-9 
National Cancer Institute. (2015). [cgvArticle]. Retrieved January 3, 2017, from 
https://www.cancer.gov/about-cancer/understanding/what-is-cancer 
Orton, R. J., Sturm, O. E., Vyshemirsky, V., Calder, M., Gilbert, D. R., & Kolch, W. 
(2005). Computational modelling of the receptor-tyrosine-kinase-
activated MAPK pathway. The Biochemical Journal, 392(Pt 2), 249–261. 
https://doi.org/10.1042/BJ20050908 
Peng, X.-H., Karna, P., Cao, Z., Jiang, B.-H., Zhou, M., & Yang, L. (2006). Cross-talk 
between epidermal growth factor receptor and hypoxia-inducible factor-
1alpha signal pathways increases resistance to apoptosis by up-regulating 
survivin gene expression. The Journal of Biological Chemistry, 281(36), 
25903–25914. https://doi.org/10.1074/jbc.M603414200 
Petit, A. M., Rak, J., Hung, M. C., Rockwell, P., Goldstein, N., Fendly, B., & Kerbel, R. 
S. (1997). Neutralizing antibodies against epidermal growth factor and 
ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial 
growth factor production by tumor cells in vitro and in vivo: angiogenic 
implications for signal transduction therapy of solid tumors. The 
American Journal of Pathology, 151(6), 1523–1530. 
Piret, J.-P., Mottet, D., Raes, M., & Michiels, C. (2002). CoCl2, a chemical inducer of 
hypoxia-inducible factor-1, and hypoxia reduce apoptotic cell death in 
hepatoma cell line HepG2. Annals of the New York Academy of Sciences, 
973, 443–447. 
Roskoski, R. (2012). ERK1/2 MAP kinases: structure, function, and regulation. 
Pharmacological Research, 66(2), 105–143. 
https://doi.org/10.1016/j.phrs.2012.04.005 
55 
 
Sang, N., Stiehl, D. P., Bohensky, J., Leshchinsky, I., Srinivas, V., & Caro, J. (2003). 
MAPK signaling up-regulates the activity of hypoxia-inducible factors by 
its effects on p300. The Journal of Biological Chemistry, 278(16), 
14013–14019. https://doi.org/10.1074/jbc.M209702200 
Scaltriti, M., & Baselga, J. (2006). The Epidermal Growth Factor Receptor Pathway: A 
Model for Targeted Therapy. Clinical Cancer Research, 12(18), 5268–
5272. https://doi.org/10.1158/1078-0432.CCR-05-1554 
Shibuya, M. (2011). Vascular Endothelial Growth Factor (VEGF) and Its Receptor 
(VEGFR) Signaling in Angiogenesis. Genes & Cancer, 2(12), 1097–
1105. https://doi.org/10.1177/1947601911423031 
Shin, J.-M., Jeong, Y.-J., Cho, H.-J., Park, K.-K., Chung, I.-K., Lee, I.-K., … Chang, Y.-
C. (2013). Melittin Suppresses HIF-1α/VEGF Expression through 
Inhibition of ERK and mTOR/p70S6K Pathway in Human Cervical 
Carcinoma Cells. PLoS ONE, 8(7). 
https://doi.org/10.1371/journal.pone.0069380 
Tétreault, M.-P., Chailler, P., Beaulieu, J.-F., Rivard, N., & Ménard, D. (2008). 
Epidermal growth factor receptor-dependent PI3K-activation promotes 
restitution of wounded human gastric epithelial monolayers. Journal of 
Cellular Physiology, 214(2), 545–557. https://doi.org/10.1002/jcp.21239 
Trisciuoglio, D., Iervolino, A., Zupi, G., & Del Bufalo, D. (2005). Involvement of PI3K 
and MAPK Signaling in bcl-2-induced Vascular Endothelial Growth 
Factor Expression in Melanoma Cells. Molecular Biology of the Cell, 
16(9), 4153–4162. https://doi.org/10.1091/mbc.E04-12-1087 
van Golen, K. L., Bao, L. W., Pan, Q., Miller, F. R., Wu, Z. F., & Merajver, S. D. 
(2002). Mitogen activated protein kinase pathway is involved in RhoC 
GTPase induced motility, invasion and angiogenesis in inflammatory 
breast cancer. Clinical & Experimental Metastasis, 19(4), 301–311. 
Vara, J. Á. F., Casado, E., de Castro, J., Cejas, P., Belda-Iniesta, C., & González-Barón, 
M. (2004). PI3K/Akt signalling pathway and cancer. Cancer Treatment 
Reviews, 30(2), 193–204. https://doi.org/10.1016/j.ctrv.2003.07.007 
Wang, F.-S., Wang, C.-J., Chen, Y.-J., Chang, P.-R., Huang, Y.-T., Sun, Y.-C., … 
Yang, K. D. (2004). Ras induction of superoxide activates ERK-
dependent angiogenic transcription factor HIF-1alpha and VEGF-A 
expression in shock wave-stimulated osteoblasts. The Journal of 
Biological Chemistry, 279(11), 10331–10337. 
https://doi.org/10.1074/jbc.M308013200 
WHO | Cancer. (2015). Retrieved January 3, 2017, from 
http://www.who.int/mediacentre/factsheets/fs297/en/ 
56 
 
Wilkins, S. E., Abboud, M. I., Hancock, R. L., & Schofield, C. J. (2016). Targeting 
Protein–Protein Interactions in the HIF System. ChemMedChem, 11(8), 
773–786. https://doi.org/10.1002/cmdc.201600012 
Wu, D., & Yotnda, P. (2011). Induction and testing of hypoxia in cell culture. Journal of 
Visualized Experiments: JoVE, (54). https://doi.org/10.3791/2899 
Xue, Y., Bi, F., Zhang, X., Zhang, S., Pan, Y., Liu, N., … Fan, D. (2006). Role of Rac1 
and Cdc42 in hypoxia induced p53 and von Hippel-Lindau suppression 
and HIF1alpha activation. International Journal of Cancer, 118(12), 
2965–2972. https://doi.org/10.1002/ijc.21763 
Zhong, H., Chiles, K., Feldser, D., Laughner, E., Hanrahan, C., Georgescu, M. M., … 
Semenza, G. L. (2000). Modulation of hypoxia-inducible factor 1alpha 
expression by the epidermal growth factor/phosphatidylinositol 3-
kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: 
implications for tumor angiogenesis and therapeutics. Cancer Research, 
60(6), 1541–1545. 
Zimna, A., & Kurpisz, M. (2015). Hypoxia-Inducible Factor-1 in Physiological and 
Pathophysiological Angiogenesis: Applications and Therapies. BioMed 
Research International, 2015, 549412. 
https://doi.org/10.1155/2015/549412 
Zundel, W., Schindler, C., Haas-Kogan, D., Koong, A., Kaper, F., Chen, E., … Giaccia, 
A. J. (2000). Loss of PTEN facilitates HIF-1-mediated gene expression. 
Genes & Development, 14(4), 391–396. 
 
 
 
 
